BRAF and melanoma: However, the relatively immediate development of resistance to these drugs is a clinical problem, in part because BRAF inhibitor-resistant (BRAFi-R) melanoma cells exhibit more progressive behavior, in particular enhanced migration, invasion and metastasis [4,6,7].